Cargando…

Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms

Carbohydrate derived fulvic acid (CHD-FA) is a heat stable low molecular weight, water soluble, cationic, colloidal material with proposed therapeutic properties. The aim of this study was to evaluate the antifungal activity of CHD-FA against Candida albicans, and to characterize its mode of action....

Descripción completa

Detalles Bibliográficos
Autores principales: Sherry, Leighann, Jose, Anto, Murray, Colin, Williams, Craig, Jones, Brian, Millington, Owain, Bagg, Jeremy, Ramage, Gordon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314872/
https://www.ncbi.nlm.nih.gov/pubmed/22479260
http://dx.doi.org/10.3389/fmicb.2012.00116
_version_ 1782228156579577856
author Sherry, Leighann
Jose, Anto
Murray, Colin
Williams, Craig
Jones, Brian
Millington, Owain
Bagg, Jeremy
Ramage, Gordon
author_facet Sherry, Leighann
Jose, Anto
Murray, Colin
Williams, Craig
Jones, Brian
Millington, Owain
Bagg, Jeremy
Ramage, Gordon
author_sort Sherry, Leighann
collection PubMed
description Carbohydrate derived fulvic acid (CHD-FA) is a heat stable low molecular weight, water soluble, cationic, colloidal material with proposed therapeutic properties. The aim of this study was to evaluate the antifungal activity of CHD-FA against Candida albicans, and to characterize its mode of action. A panel of C. albicans isolates (n = 50) derived from a range of clinical specimens were grown planktonically and as biofilms, and the minimum inhibitory concentrations determined. Scanning electron microscopy was performed to examine ultrastructural changes and different cell membrane assays were used to determine its mode of action. In addition, the role of C. albicans biofilm resistance mechanisms were investigated to determine their effects on CHD-FA activity. CHD-FA was active against planktonic and sessile C. albicans at concentrations 0.125 and 0.25% respectively, and was shown to be fungicidal, acting through disruption of the cell membrane activity. Resistance mechanisms, including matrix, efflux, and stress, had a limited role upon CHD-FA activity. Overall, based on the promising in vitro spectrum of activity and minimal biofilm resistance of the natural and cheap antiseptic CHD-FA, further studies are required to determine its applicability for clinical use.
format Online
Article
Text
id pubmed-3314872
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-33148722012-04-04 Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms Sherry, Leighann Jose, Anto Murray, Colin Williams, Craig Jones, Brian Millington, Owain Bagg, Jeremy Ramage, Gordon Front Microbiol Microbiology Carbohydrate derived fulvic acid (CHD-FA) is a heat stable low molecular weight, water soluble, cationic, colloidal material with proposed therapeutic properties. The aim of this study was to evaluate the antifungal activity of CHD-FA against Candida albicans, and to characterize its mode of action. A panel of C. albicans isolates (n = 50) derived from a range of clinical specimens were grown planktonically and as biofilms, and the minimum inhibitory concentrations determined. Scanning electron microscopy was performed to examine ultrastructural changes and different cell membrane assays were used to determine its mode of action. In addition, the role of C. albicans biofilm resistance mechanisms were investigated to determine their effects on CHD-FA activity. CHD-FA was active against planktonic and sessile C. albicans at concentrations 0.125 and 0.25% respectively, and was shown to be fungicidal, acting through disruption of the cell membrane activity. Resistance mechanisms, including matrix, efflux, and stress, had a limited role upon CHD-FA activity. Overall, based on the promising in vitro spectrum of activity and minimal biofilm resistance of the natural and cheap antiseptic CHD-FA, further studies are required to determine its applicability for clinical use. Frontiers Research Foundation 2012-03-29 /pmc/articles/PMC3314872/ /pubmed/22479260 http://dx.doi.org/10.3389/fmicb.2012.00116 Text en Copyright © 2012 Sherry, Jose, Murray, Williams, Jones, Millington, Bagg and Ramage. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
spellingShingle Microbiology
Sherry, Leighann
Jose, Anto
Murray, Colin
Williams, Craig
Jones, Brian
Millington, Owain
Bagg, Jeremy
Ramage, Gordon
Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms
title Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms
title_full Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms
title_fullStr Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms
title_full_unstemmed Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms
title_short Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms
title_sort carbohydrate derived fulvic acid: an in vitro investigation of a novel membrane active antiseptic agent against candida albicans biofilms
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314872/
https://www.ncbi.nlm.nih.gov/pubmed/22479260
http://dx.doi.org/10.3389/fmicb.2012.00116
work_keys_str_mv AT sherryleighann carbohydratederivedfulvicacidaninvitroinvestigationofanovelmembraneactiveantisepticagentagainstcandidaalbicansbiofilms
AT joseanto carbohydratederivedfulvicacidaninvitroinvestigationofanovelmembraneactiveantisepticagentagainstcandidaalbicansbiofilms
AT murraycolin carbohydratederivedfulvicacidaninvitroinvestigationofanovelmembraneactiveantisepticagentagainstcandidaalbicansbiofilms
AT williamscraig carbohydratederivedfulvicacidaninvitroinvestigationofanovelmembraneactiveantisepticagentagainstcandidaalbicansbiofilms
AT jonesbrian carbohydratederivedfulvicacidaninvitroinvestigationofanovelmembraneactiveantisepticagentagainstcandidaalbicansbiofilms
AT millingtonowain carbohydratederivedfulvicacidaninvitroinvestigationofanovelmembraneactiveantisepticagentagainstcandidaalbicansbiofilms
AT baggjeremy carbohydratederivedfulvicacidaninvitroinvestigationofanovelmembraneactiveantisepticagentagainstcandidaalbicansbiofilms
AT ramagegordon carbohydratederivedfulvicacidaninvitroinvestigationofanovelmembraneactiveantisepticagentagainstcandidaalbicansbiofilms